DE69616358T2 - Kristalline form iii des hemi calcium salzes von [r-(r*,r*)]-2-(4-fluorphenyl)-beta-delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrol-1-heptansäure (atorvastatin) - Google Patents
Kristalline form iii des hemi calcium salzes von [r-(r*,r*)]-2-(4-fluorphenyl)-beta-delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrol-1-heptansäure (atorvastatin)Info
- Publication number
- DE69616358T2 DE69616358T2 DE69616358T DE69616358T DE69616358T2 DE 69616358 T2 DE69616358 T2 DE 69616358T2 DE 69616358 T DE69616358 T DE 69616358T DE 69616358 T DE69616358 T DE 69616358T DE 69616358 T2 DE69616358 T2 DE 69616358T2
- Authority
- DE
- Germany
- Prior art keywords
- fluorphenyl
- atorvastatin
- pyrrol
- phenylamino
- methylethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60145495A | 1995-07-17 | 1995-07-17 | |
PCT/US1996/011367 WO1997003958A1 (en) | 1995-07-17 | 1996-07-08 | Form iii crystalline (r-(r*,r*)-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69616358D1 DE69616358D1 (de) | 2001-11-29 |
DE69616358T2 true DE69616358T2 (de) | 2002-07-04 |
Family
ID=24407538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69616358T Expired - Lifetime DE69616358T2 (de) | 1995-07-17 | 1996-07-08 | Kristalline form iii des hemi calcium salzes von [r-(r*,r*)]-2-(4-fluorphenyl)-beta-delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrol-1-heptansäure (atorvastatin) |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0848704B2 (de) |
CY (1) | CY2356B1 (de) |
DE (1) | DE69616358T2 (de) |
PT (1) | PT848704E (de) |
SI (1) | SI0848704T1 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ296967B6 (cs) * | 2002-02-01 | 2006-08-16 | Zentiva, A.S. | Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) |
CA2633268A1 (en) | 2005-12-13 | 2007-06-21 | Teva Pharmaceutical Industries Ltd. | Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
EP3272336A1 (de) | 2016-07-19 | 2018-01-24 | Stada Arzneimittel Ag | Atorvastatin-zusammensetzung |
-
1996
- 1996-07-08 SI SI9630356T patent/SI0848704T1/xx unknown
- 1996-07-08 PT PT96924367T patent/PT848704E/pt unknown
- 1996-07-08 DE DE69616358T patent/DE69616358T2/de not_active Expired - Lifetime
- 1996-07-08 EP EP96924367A patent/EP0848704B2/de not_active Expired - Lifetime
-
2003
- 2003-03-06 CY CY0300020A patent/CY2356B1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP0848704B1 (de) | 2001-10-24 |
EP0848704B2 (de) | 2009-12-16 |
CY2356B1 (en) | 2004-06-04 |
DE69616358D1 (de) | 2001-11-29 |
EP0848704A1 (de) | 1998-06-24 |
PT848704E (pt) | 2002-03-28 |
SI0848704T1 (en) | 2002-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE208375T1 (de) | Kristallines (r-(r*,r*))-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- ((phenylamino)carbonyl)-1h-pyrrol-1- heptancarbonsäure hemi calcium salz (atorvastatin) | |
DK0839132T5 (da) | Fremgangsmåde til fremstilling af amorft [R-(R*,R*)]-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyrecalciumsalt (2:1) | |
TWI319396B (en) | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) | |
ATE207465T1 (de) | Kristalline form iii des hemi calcium salzes von (r-(r*,r*))-2-(4-fluorphenyl)-beta-delta- dihydroxy-5-(1-methylethyl)-3-phenyl-4- ((phenylamino)carbonyl)-1h-pyrrol-1-heptansäure (atorvastatin) | |
HUP0700116A2 (en) | Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-betha,gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-heptanoic acid calcium salt (2:1) | |
DE69616358D1 (de) | Kristalline form iii des hemi calcium salzes von [r-(r*,r*)]-2-(4-fluorphenyl)-beta-delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrol-1-heptansäure (atorvastatin) | |
NO975499D0 (no) | Form III krystallinsk (R-(R*,R*)-2(4-fluorfenyl)-<beta>-<delta>-dihydroksy-(1-metyl-etyl)-3-fenyl-4-(fenylamino)karbonyl)-1H-pyrrol-1-heptansyre-hemi-kalsiumsalt | |
NZ507836A (en) | Crystalline [r*(r* ,r*)]-2-(4-flurophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) | |
AU2001234058A1 (en) | Form v crystalline (r-(r*,r*))-2-(4-fluorophenyl)-ss,$g(d)-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1- heptanoic acid hemi calcium salt. (atorvastatin) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: WARNER-LAMBERT COMPANY LLC (N. D. GES. D. STAATES |
|
8366 | Restricted maintained after opposition proceedings | ||
8328 | Change in the person/name/address of the agent |
Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336 |
|
8332 | No legal effect for de |